In 2020, when China’s EV population was only around 3 million, CDH keenly noticed that EV replacing petrol vehicle was destined, and seized the investment opportunity of TELD at an excellent time. “All the other investors were hesitated, but the VGC team made a thorough research, understood us the most”, and quickly formed conclusion. So when everybody was not optimistic, CDH was the first to make the investment decision. After CDH’s investment, major policies such as “new infrastructure” and “carbon neutral” were launched, increasing the sales of EV rapidly. As the leading operator of charging network, TELD ranks 1st by total number of charging piles, total amount of electricity charged, and utilization rate. TELD’s unique technologies including “grouping control”, “bidirectional inverters”, “Microgrid” etc，can effectively balance the mismatches between supply and demand. TELD’s new concept of turning EVs into a “virtual power plant” will greatly promote China’s energy transformation.

In July 2019, CDH VGC and Sinopharm led the first round investment of RMB160 million in GemPharmatech. Founded in 2017, GemPharmatech has become the world's largest genetically modified mouse models provider in just five years.  The company has created a collection of over 20,000+ genetically engineered mouse models (GEMMs) for research and drug development. The company has successfully proven that "China's intelligent mice" can be exported globally and has broken the "dilemma" of domestic mouse model enterprises to become an internationally recognized standard. On April 25, 2022, GemPharmatech successfully completed its IPO on Shanghai’s Science and Technology Innovation Board (Stock Code: 688046).

In 2011, with its expertise and sincerity, CDH stood out from dozens of investors and became the only financial investor of Kanghong Pharmaceutical. After the investment, the company's proprietary Class 1 innovative drug "Conbercept" was launched in China. This is China’s first domestic biological drug, with proprietary intellectual property rights, to be officially endorsed by WHO. It was the first domestically developed product, and broke the monopoly of imported drugs. Conbercept has greatly reduced patient expenditures and increased utilization rates, creating huge social impact as well as economic value. At the same time, Conbercept brought rapid growth in revenue, which helped Kanghong completed the A-share listing in 2015. CDH has accurately catch the turning point of the pharmaceutical industry in China, where innovative drugs took the place of generics as the new market dominator. It is also a remarkable milestone for Kanghong to realize its value from R&D to market as a leader in China’s pharmaceutical industry. CDH's "deep dive" industry research, "sharp and insightful“ understanding of industrial trends, "precisely positioning" of industry leaders, and stronge execution of "fundraising, investment, management and exit" eventually made a huge success out of the investment in Kanghong.